Inhibition of cell proliferation and migration in non‑small cell lung cancer cells through the suppression of LYPLA1

Mohammed,Anaz; Zhang,Caixin; Zhang ,Shuwen; Shen,Qin; Li,Jieying; Tang,Zhiyuan; Liu,Hua

doi:10.3892/or.2018.6857

Inhibition of cell proliferation and migration in non‑small cell lung cancer cells through the suppression of LYPLA1

Authors:
- Anaz Mohammed
- Caixin Zhang
- Shuwen Zhang
- Qin Shen
- Jieying Li
- Zhiyuan Tang
- Hua Liu
View Affiliations

Affiliations: Department of Respiratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Pathology, Medical School of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: November 9, 2018 https://doi.org/10.3892/or.2018.6857
Pages: 973-980

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lysophospholipase1 (LYPLA1) also known as acyl‑protein thioesterase1 (APT1) belongs to the superfamily of α/β hydrolase. It has been found to have the properties of a homodimer by manifesting depalmitoylation as well as lysophospholipase activity. LYPLAs are under the control of both microRNAs, miR‑138 and miR‑424. They were observed to be significantly overexpressed in chronic lymphocytic leukemia cells. To date, LYPLAs are the sole enzymes recognized to activate depalmitoylation. In this study, we provide the expression pattern of LYPLA1 in non‑small cell lung cancer (NSCLC) using four different NSCLC cell lines. Western blot analysis and RT‑PCR were performed to detect the protein expression and mRNA expression of LYPLA1 in NSCLC cell lines. We detected the highest LYPLA1 protein expression level in SPC‑A‑1 cells followed by A549 cells, and the highest LYPLA1 mRNA expression level was detected in the SPC‑A‑1 cells followed by the H1299 cell line. We found that suppression of LYPLA1 expression using small‑interfering RNA significantly inhibited proliferation, migration and invasion of the LYPLA1‑transfected NSCLC cells. Furthermore, we explored the involvement of LYPLA1 in the regulation of epithelial‑mesenchymal transition (EMT). The epithelial marker E‑cadherin was significantly increased, while mesenchymal markers N‑cadherin, vimentin and SNAIL were markedly decreased in the LYPLA1‑silenced cells. Collectively the results of the present study suggest that the LYPLA1 gene plays a tumor‑promotor role in NSCLC cells in vitro.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Qiu ZL, Shen CT, Sun ZK, Wei WJ, Zhang XY, Song HJ and Luo QY: Circulating long non-coding RNAs act as biomarkers for predicting 131I uptake and mortality in papillary thyroid cancer patients with lung metastases. Cell Physiol Biochem. 40:1377–1390. 2016. View Article : Google Scholar : PubMed/NCBI
3	Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS and Hainaut P: Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 21:7435–7451. 2002. View Article : Google Scholar : PubMed/NCBI
4	Zhang H and Cai B: The impact of tobacco on lung health in China. Respirology. 8:17–21. 2003. View Article : Google Scholar : PubMed/NCBI
5	Furrukh M: Tobacco smoking and lung cancer: Perception-changing facts. Sultan Qaboos Univ Med J. 13:345–358. 2013. View Article : Google Scholar : PubMed/NCBI
6	Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E and Ramalingam SS: Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 25:5570–5577. 2007. View Article : Google Scholar : PubMed/NCBI
7	Finn OJ: Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 23 Suppl 8:viii6–viii9. 2012. View Article : Google Scholar : PubMed/NCBI
8	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
9	Takeda M, Okamoto I, Sakai K, Kawakami H, Nishio K and Nakagawa K: Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Ann Oncol. 23:2931–2936. 2012. View Article : Google Scholar : PubMed/NCBI
10	Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ and Kurzrock R: Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol. 6:1601–1612. 2011. View Article : Google Scholar : PubMed/NCBI
11	Minguet J, Smith KH and Bramlage P: Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives. Int J Cancer. 138:2549–2561. 2016. View Article : Google Scholar : PubMed/NCBI
12	Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E and Detterbeck F: American College of Chest Physicians: Noninvasive staging of non-small cell lung cancer. ACCP evidenced-based clinical practice guidelines (2nd edition) Chest. 132 (3 Suppl):S178–S201. 2007.
13	Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, Chan JK and Owens DK: Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: A meta-analysis. Ann Intern Med. 139:879–892. 2003. View Article : Google Scholar : PubMed/NCBI
14	Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D and de Vet HC: Standards for Reporting of Diagnostic Accuracy: Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. Radiology. 226:24–28. 2003. View Article : Google Scholar : PubMed/NCBI
15	Bille A, Pelosi E, Skanjeti A, Arena V, Errico L, Borasio P, Mancini M and Ardissone F: Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: Accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg. 36:440–445. 2009. View Article : Google Scholar : PubMed/NCBI
16	Kong E, Peng S, Chandra G, Sarkar C, Zhang Z, Bagh MB and Mukherjee AB: Dynamic palmitoylation links cytosol-membrane shuttling of Acyl-protein thioesterase-1 and Acyl-protein thioesterase-2 with that of proto-oncogene H-ras product and growth-associated protein-43. J Biol Chem. 288:9112–9125. 2013. View Article : Google Scholar : PubMed/NCBI
17	Berg V, Rusch M, Vartak N, Jüngst C, Schauss A, Waldmann H, Hedberg C, Pallasch CP, Bastiaens PI, Hallek M, et al: miRs-138 and −424 control palmitoylation-dependent CD95-mediated cell death by targeting acyl protein thioesterases 1 and 2 in CLL. Blood. 125:2948–2957. 2015. View Article : Google Scholar : PubMed/NCBI
18	Magee AI and Courtneidge SA: Two classes of fatty acid acylated proteins exist in eukaryotic cells. EMBO J. 4:1137–1144. 1985. View Article : Google Scholar : PubMed/NCBI
19	Magee AI, Gutierrez L, McKay IA, Marshall CJ and Hall A: Dynamic fatty acylation of p21N-ras. EMBO J. 6:3353–3357. 1987. View Article : Google Scholar : PubMed/NCBI
20	Martin BR, Wang C, Adibekian A, Tully SE and Cravatt BF: Global profiling of dynamic protein palmitoylation. Nat Methods. 9:84–89. 2012. View Article : Google Scholar
21	Duncan JA and Gilman AG: A cytoplasmic acyl-protein thioesterase that removes palmitate from G protein alpha subunits and p21(RAS). J Biol Chem. 273:15830–15837. 1998. View Article : Google Scholar : PubMed/NCBI
22	Smotrys JE and Linder ME: Palmitoylation of intracellular signaling proteins: Regulation and function. Annu Rev Biochem. 73:559–587. 2004. View Article : Google Scholar : PubMed/NCBI
23	Sato G: Tissue culture: The unrealized potential. Cytotechnology. 57:111–114. 2008. View Article : Google Scholar : PubMed/NCBI
24	Stratton MR, Campbell PJ and Futreal PA: The cancer genome. Nature. 458:719–724. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wistuba II, Bryant D, Behrens C, Milchgrub S, Virmani AK, Ashfaq R, Minna JD and Gazdar AF: Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin Cancer Res. 5:991–1000. 1999.PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Linder ME and Deschenes RJ: Palmitoylation: Policing protein stability and traffic. Nat Rev Mol Cell Biol. 8:74–84. 2007. View Article : Google Scholar : PubMed/NCBI
28	Bijlmakers MJ and Marsh M: The on-off story of protein palmitoylation. Trends Cell Biol. 13:32–42. 2003. View Article : Google Scholar : PubMed/NCBI
29	Resh MD: Palmitoylation of ligands receptors and intracellular signaling molecules. Sci STKE. 2006:re142006. View Article : Google Scholar : PubMed/NCBI
30	Salaun C, Greaves J and Chamberlain LH: Intracellular dynamic of protein palmitoylation. J Cell Biol. 191:1229–1238. 2010. View Article : Google Scholar : PubMed/NCBI
31	Hellsten E, Vesa J, Olkkonen VM, Jalanko A and Peltonen L: Human palmitoyl protein thioesterase: Evidence for lysosomal targeting of the enzyme and disturbed cellular routing in infantile neuronal ceroid lipofuscinosis. EMBO J. 15:5240–5245. 1996. View Article : Google Scholar : PubMed/NCBI
32	Chang A: Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10. 2011. View Article : Google Scholar : PubMed/NCBI
33	Willers H, Azzoli CG, Santivasi WL and Xia F: Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. Cancer J. 19:200–207. 2013. View Article : Google Scholar : PubMed/NCBI
34	Xie D, Lan L, Huang K, Chen L, Xu C, Wang R, Shi Y, Wu X, Wang L, Liu Y and Lu B: Association of p53/p21 expression and cigarette smoking with tumor progression and poor prognosis in non-small cell lung cancer patients. Oncol Rep. 32:2517–2526. 2014. View Article : Google Scholar : PubMed/NCBI
35	Lee EY and Muller WJ: Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol. 2:a0032362010. View Article : Google Scholar : PubMed/NCBI
36	Lee KW, Kim JH, Han S, Sung CO, Do IG, Ko YH, Um SH and Kim SH: Twist1 is an independent prognostic factor of esophageal squamous cell carcinoma and associated with its epithelial-mesenchymal transition. Ann Surg Oncol. 19:326–335. 2012. View Article : Google Scholar : PubMed/NCBI
37	Yi ZY, Feng LJ, Xiang Z and Yao H: Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in hepatocellular carcinoma cells. J Invest Surg. 24:67–76. 2011. View Article : Google Scholar : PubMed/NCBI
38	Xu X, Zhu Y, Liang Z, Li S, Xu X, Wang X, Wu J, Hu Z, Meng S, Liu B, et al: c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial-mesenchymal transition in bladder cancer by regulating Akt/GSK-3β/Snail signaling. Cell Death Dis. 7:e20882016. View Article : Google Scholar : PubMed/NCBI
39	Miettinen PJ, Ebner R, Lopez AR and Derynck R: TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: Involvement of type I receptors. J Cell Biol. 127:2021–2036. 1994. View Article : Google Scholar : PubMed/NCBI
40	Bucay N, Bhagirath D, Sekhon K, Yang T, Fukuhara S, Majid S, Shahryari V, Tabatabai Z, Greene KL, Hashimoto Y, et al: A novel microRNA regulator of prostate cancer epithelial-mesenchymal transition. Cell Death Differ. 24:1263–1274. 2017. View Article : Google Scholar : PubMed/NCBI
41	Qiao Y, Jiang X, Lee ST, Karuturi RK, Hooi SC and Yu Q: FOXQ1 regulates epithelial-mesenchymal transition in human cancers. Cancer Res. 71:3076–3086. 2011. View Article : Google Scholar : PubMed/NCBI
42	Van Roy F and Berx G: The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 65:3756–3788. 2008. View Article : Google Scholar : PubMed/NCBI